AHA shares proposals to lower Medicare drug prices with Congress

In a statement submitted to the Senate Finance Committee for a hearing yesterday on lowering drug prices in Medicare, AHA encouraged Congress to implement policies that would increase generic alternatives and discourage anti-competitive tactics while maintaining incentives to develop innovative new therapies. AHA also called for policies to increase transparency in drug pricing; provide rebates to Medicare when a drug’s average manufacturer or sales price exceeds inflation; better align incentives in the Part D reinsurance program; and protect the 340B Drug Pricing Program.
Related News Articles
Headline
The AHA Sept. 15 expressed support for the Ensuring Access to Essential Providers Act, legislation that would require Medicare Advantage plans to cover…
Headline
Newsweek’s Access Health newsletter today features a conversation with AHA Chair Tina Freese Decker, president and CEO of Corewell Health in Michigan, where…
Headline
The House Energy and Commerce Subcommittee on Health Sept. 10 advanced the Title VIII Nursing Workforce Reauthorization Act (H.R. 3593), AHA-supported…
Headline
The House Appropriations Committee Sept. 9 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services, Education…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Perspective
Congress returns to Washington, D.C., this week facing a long list of things to do, including several that will impact hospitals’ ability to provide access to…